Ads
related to: what happened to alnylam pharmaceuticals newsLearn about treatment with AMVUTTRA® (vutrisiran). More information about AMVUTTRA® (vutrisiran) is within reach.
- How AMVUTTRA Was Studied
See how safety and efficacy
were evaluated in the study.
- See How AMVUTTRA Works
View a diagram that explains
how AMVUTTRA works.
- Find a Treatment Center
Locate the treatment center
closest to you.
- View Dosing Information
AMVUTTRA is given
by an HCP.
- Study Results
See the results of the clinical
study for AMVUTTRA.
- Resources for Patients
Find educational resources for you
and your family.
- How AMVUTTRA Was Studied
Once enrolled, an Alnylam Assist® Case Manager can partner with you. They provide support services such as connecting you with disease education resources.
Learn About Our Efforts to Improve the Lives of Patients, Employees and Our Communities. We Bring Together the Brightest Minds, Invest in Science and Take Smart Risks.
Search results
- The rare disease specialist beat Wall Street's expectations with strong revenue growth and smaller-than-anticipated losses. Alnylam Pharmaceuticals (ALNY -1.20%), a leader in RNA interference (RNAi) therapeutics, released its first-quarter earnings on May 2, revealing substantial year-over-year growth and pipeline advancements.
www.fool.com › data-news › 2024/05/10Alnylam Pharmaceuticals Outperformed in Q1 | The Motley Fool
People also ask
What happened to Alnylam Pharmaceuticals?
Is Alnylam Pharmaceuticals (ALNY) poised to post a new all-time high?
Who is Alnylam Pharmaceuticals?
Why did Alnylam Pharmaceuticals' share price rise 3%?
Feb 15, 2024 · CAMBRIDGE, Mass., February 15, 2024--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the fourth...
Jul 17, 2023 · What happened. The fight against Alzheimer's disease seems to be advancing, and one biotech developing a treatment for the degenerative brain disorder benefited from this on Monday.
May 10, 2024 · Free Article. Alnylam Pharmaceuticals Outperformed in Q1. By JesterAI – May 10, 2024 at 6:51PM. Key Points. Earnings per share -- though negative -- significantly exceeded analysts'...
- What Happened
- So What
- Now What
Shares of Alnylam Pharmaceuticals (ALNY-0.28%)are poised to post a new all-time high upon market open Wednesday. The RNA interference (RNAi) drug specialist's stock price rose by as much as 53% in premarket action this morning. What's fueling this supercharged move higher today? Ahead of the opening bell, Alnylam announced that its closely watched ...
The biotechsaid that this novel gene silencer also met the study's first secondary endpoint of change from baseline in quality of life compared to placebo. Patisiran, however, did not pass the point of statistical significance on the study's secondary composite endpoint of all-cause mortality. Alnylam said additional details on the study's results ...
Is Alnylam stock still a buy after its meteoric rise this morning? I believe so. The company's novel RNAi platform took a major step forward with this late-stage success, putting it on track for enormous levels of organic growth in the years to come. Moreover, the company offers investors a second way to win through a possible buyout.
- George Budwell
Oct 28, 2021 · October 28, 2021 — 01:48 pm EDT. Written by Brett Schafer for The Motley Fool -> What happened. Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) were tanking on Thursday after the company...
Insider Monkey • 13 days ago. ALNY. +2.59% Alnylam (ALNY) Q1 Loss Narrower Than Expected, Sales Rise Y/Y. Alnylam (ALNY) reports better-than-expected first-quarter 2024 results as both earnings...
Feb 15, 2024 · Shares of Alnylam Pharmaceuticals (NASDAQ: ALNY) were sinking 9.5% lower as of 11:27 a.m. ET on Thursday after falling as much as 12.6% earlier in the day. The sell-off came after the drugmaker...
Ads
related to: what happened to alnylam pharmaceuticals newsLearn about treatment with AMVUTTRA® (vutrisiran). More information about AMVUTTRA® (vutrisiran) is within reach.
Once enrolled, an Alnylam Assist® Case Manager can partner with you. They provide support services such as connecting you with disease education resources.
Learn About Our Efforts to Improve the Lives of Patients, Employees and Our Communities. We Bring Together the Brightest Minds, Invest in Science and Take Smart Risks.
